Sugi Predict

Sugi Predict / Compounds / SCHEMBL215965

SCHEMBL215965

SCHEMBL215965

CC(=O)OCCC(C)CCCC(C)CCCC(C)CCCC(C)C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 4/20 0.58
▸ ALOX15 P16050 2/20 0.58
▸ BLM P54132 1/20 0.52
▸ LMNA P02545 1/20 0.50
▸ ALDH1A1 P00352 2/20 0.43
▸ EGFR P00533 2/20 0.39
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CHRM5 P08912 2/20 0.38
▸ CHRM1 P11229 2/20 0.38
▸ CHRM3 P20309 2/20 0.38
▸ PGR P06401 1/20 0.38
▸ CHRM2 P08172 1/20 0.38
▸ CHRM4 P08173 1/20 0.38
▸ HTR1A P08908 1/20 0.38
▸ CHRNB2 P17787 1/20 0.38
▸ TBXA2R P21731 1/20 0.38
▸ CHRNB4 P30926 1/20 0.38
▸ CHRNA3 P32297 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL997389 1.00 PTPN1 (0.58) PTPN1ALOX15BLMLMNAALDH1A1
SCHEMBL997391 1.00 PTPN1 (0.58) PTPN1ALOX15BLMLMNAALDH1A1
SCHEMBL872939 1.00 PTPN1 (0.58) PTPN1ALOX15BLMLMNAALDH1A1
SCHEMBL3505233 1.00 PTPN1 (0.58) PTPN1ALOX15BLMLMNAALDH1A1
SCHEMBL14094312 0.92 PTPN1 (0.58) PTPN1ALOX15BLMLMNAALDH1A1
SCHEMBL16048661 0.92 PTPN1 (0.58) PTPN1ALOX15BLMLMNAALDH1A1
SCHEMBL31412851 0.89 PTPN1 (0.55) PTPN1ALOX15BLMLMNAALDH1A1
SCHEMBL16166818 0.89 PTPN1 (0.55) PTPN1ALOX15BLMLMNAALDH1A1
SCHEMBL25341538 0.88 ALOX15 (0.61) PTPN1ALOX15BLMLMNAALDH1A1
SCHEMBL7552905 0.87 ALOX15 (0.70) PTPN1ALOX15LMNAALDH1A1CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088395-B2 Phytol derived immunoadjuvants and their use in vaccine formulations INDIANA STATE UNIVERSITY (US) 2012-01-03 — — US claimed
CN-101404985-A Autoimmune conditions and NADPH oxidase defects BIOVITRUM AB PUBL (SE) 2009-04-08 — — CN claimed
EP-2004159-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS Biovitrum AB (publ) (SE) 2008-12-24 — — EP claimed
US-20080051451-A1 Autoimmune conditions and NADPH oxidase defects BIOVITRUM AB (SE) 2008-02-28 — — US claimed
WO-2007104790-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS BIOVITRUM AB (PUBL) (SE) 2007-09-20 — — WO claimed
US-20060292163-A1 PHYTOL DERIVED IMMUNOADJUVANTS AND THEIR USE IN VACCINE FORMULATIONS INDIANA STATE UNIVERSITY 2006-12-28 — — US claimed
US-20050158329-A1 Novel phytol derived immunoadjuvants and their use in vaccine formulations GHOSH SWAPAN K (US) 2005-07-21 — — US claimed
CN-117752036-A Method for removing fishy smell of venison 沈阳农业大学 2024-03-26 — — CN disclosed
US-8088395-B2 Phytol derived immunoadjuvants and their use in vaccine formulations INDIANA STATE UNIVERSITY (US) 2012-01-03 — — US disclosed
EP-1380293-A9 BONE METABOLISM IMPROVING AGENTS The Nisshin OilliO Group, Ltd. (JP) 2009-09-23 — — EP disclosed
US-7579374-B2 Agent for improving bone metabolism THE NISSHIN OILLIO GROUP, LTD. (JP) 2009-08-25 — — US disclosed
CN-101404985-A Autoimmune conditions and NADPH oxidase defects BIOVITRUM AB PUBL (SE) 2009-04-08 — — CN disclosed
EP-2004159-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS Biovitrum AB (publ) (SE) 2008-12-24 — — EP disclosed
US-20080051451-A1 Autoimmune conditions and NADPH oxidase defects BIOVITRUM AB (SE) 2008-02-28 — — US disclosed
WO-2007104790-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS BIOVITRUM AB (PUBL) (SE) 2007-09-20 — — WO disclosed
WO-2007104790-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS BIOVITRUM AB (PUBL) (SE) 2007-09-20 — — WO disclosed
US-20060292163-A1 PHYTOL DERIVED IMMUNOADJUVANTS AND THEIR USE IN VACCINE FORMULATIONS INDIANA STATE UNIVERSITY 2006-12-28 — — US disclosed
US-20050158329-A1 Novel phytol derived immunoadjuvants and their use in vaccine formulations GHOSH SWAPAN K (US) 2005-07-21 — — US disclosed
US-20040058995-A1 Agent for improving bone metabolism THE NISSHIN OILLIO, LTD. 2004-03-25 — — US disclosed
US-4168271-A Unsaturated vitamin E intermediates--dehydro and didehydro α-tocopherols SCM CORPORATION (US) 1979-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051451-A1 Autoimmune conditions and NADPH oxidase defects CYBB, NOX1, NOX5 PTPN1 790/4885ALOX15 31/4885BLM 2996/4885
US-20040058995-A1 Agent for improving bone metabolism FABP2, FABP4, SREBF2 PTPN1 4636/4885ALOX15 263/4885BLM 4705/4885
US-20050158329-A1 Novel phytol derived immunoadjuvants and their use in vaccine formulations CD47, TSG101, LY96 PTPN1 475/4885ALOX15 810/4885BLM 1167/4885
US-20060292163-A1 PHYTOL DERIVED IMMUNOADJUVANTS AND THEIR USE IN VACCINE FORMULATIONS CD47, LY96, CD4 PTPN1 317/4885ALOX15 492/4885BLM 946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.